Clinical Thought
Improving Enrollment of African American Patients in Clinical Trials for Multiple Myeloma
Release Date: August 24, 2021
Expiration Date: August 23, 2022
Not certified for credit.
Begin »
Program Overview
Program Description
Although the incidence of multiple myeloma is higher in African Americans than in Whites, African American patients are vastly underrepresented in myeloma clinical trials. Systematic review of multiple clinical trials reveals that the racial gap in trial enrollment has persisted for decades and will likely continue without intervention. In this activity, Dr Pritesh Patel discusses the critical role clinicians play in educating patients about treatment options, engaging patients in decision-making, and referring patients to clinical trials. Strategies to improve communication, education, and advocacy for African American patients with multiple myeloma can help to ensure balanced and timely referral to clinical trials with the opportunity for improved outcomes.
Target Audience
Oncology NPs, PAs, and nurses
Faculty
Pritesh Patel, MD
- Associate Professor of Clinical Medicine
- Division of Hematology/Oncology
- Associate Director
- Blood and Marrow Transplant Program
- University of Illinois at Chicago
- Chicago, Illinois
Details
This activity is supported by educational grants from AbbVie Inc., Amgen, Bristol-Myers Squibb Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose to the audience all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Patel: consulting fees/fees for non-CME/CE services: Amgen, Celgene/BMS; fees for non-CME/CE services: Janssen.
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 102521AJ-CT2